secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAIA Biotechnology, Inc. (MAIA)
CIK:        0001878313
Form:       8-K
Filed at:   2025-06-18T23:59:59+00:00
Accession:  0001641172-25-015524
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MAIA signs master clinical supply agreement with Roche for ateganosine-atezolizumab combo studies
--------------------------------------------------------------------------------

- Agreement supports future studies combining MAIA's ateganosine (THIO) with Roche's atezolizumab (Tecentriq) for multiple hard-to-treat cancers.
- Preclinical data showed ateganosine highly synergistic and effective with anti-PD-L1 agent atezolizumab.
- Ateganosine is a first-in-class telomere-targeting agent in clinical development for NSCLC after checkpoint inhibitor progression.
- CEO Vlad Vitoc said partnership with Roche strengthens mission to find safe and effective cancer treatments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1878313/000164117225015524/0001641172-25-015524-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1878313/000164117225015524/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-015524

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer